Citation Impact
Citing Papers
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action
2005
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
2002
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
2001
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
1994
Untangling the ErbB signalling network
2001 Standout
Role of Herceptin<sup>®</sup> in Primary Breast Cancer: Views from North America and Europe
2001
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
2000
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
2001
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
2003
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
2003
ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
2003
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
2016
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status
2004
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
2005
MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo
1995
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
1998
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
1998
Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients
2000
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
2002
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
1994
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
2001
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
2004
Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cellsin Vivo1
2000
Cyclin E as a prognostic and predictive marker in breast cancer
2005
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
2000 Standout
Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors
2007
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor
2000
The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans
1997 StandoutNatureNobel
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Antiestrogens: Mechanisms and actions in target cells
1995
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
2002 Standout
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
Insulin-like growth factors and neoplasia
2004
Cancer drug resistance: an evolving paradigm
2013 Standout
Genetic instabilities in human cancers
1998 StandoutNature
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells
1999
The antioxidant action of a pure antioestrogen: Ability to inhibit lipid peroxidation compared to tamoxifen and 17β-oestradiol and relevance to its anticancer potential
1994
Naturally occurring B-cell responses to breast cancer
2003
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
2010
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
The Bcl2 family: regulators of the cellular life-or-death switch
2002 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Cellular functions of plasma membrane estrogen receptors
2002
Lymphangiogenesis in development and human disease
2005 StandoutNature
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Clinical potential of new antiestrogens.
1997
Historical perspective on hormonal therapy of advanced breast cancer
2002
A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm
2002 Nature
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
2005
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells
1997
Chemical remodelling of cell surfaces in living animals
2004 StandoutNatureNobel
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)
2008
Male breast cancer
2006 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
2003
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
1998
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
1998 Standout
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
2005
The role of angiogenic growth factors in breast cancer progression
1996
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
1990
Human breast carcinoma desmoplasia is PDGF initiated
2000
Molecular basis of agonism and antagonism in the oestrogen receptor
1997 StandoutNature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
2000
Status of HER-2 in male and female breast carcinoma
2001
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
1995
Antiestrogens: Mechanisms of action and resistance in breast cancer
1997
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
2004
Fibroblasts in cancer
2006 Standout
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
2002 Standout
Platelet-Derived Growth Factor Receptor Association with Na+/H+ Exchanger Regulatory Factor Potentiates Receptor Activity
2000 StandoutNobel
Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
2015 StandoutNobel
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
Recent insights into platinum drug resistance in cancer
1998
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
1999
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Exosomes: composition, biogenesis and function
2002 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Deconstructing the molecular portraits of breast cancer
2010
Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer
2008
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
Fluorine in medicinal chemistry
2007 Standout
Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.
2003
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
2007
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
2009
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors.
1996
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen
1997
Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
1993 Standout
Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors
2001
Insulin-like growth factor II acts through an endogenous growth pathway regulated by imprinting in early mouse embryos.
1992
The Type 1 Insulin-Like Growth Factor Receptor Pathway
2008
A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.
1996
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
2008
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
2002 StandoutScience
Estrogen Receptor Molecular Biology
1994
Role of insulin-like growth factors in embryonic and postnatal growth
1993 Standout
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
1998 StandoutScience
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
2007
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation.
1996
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.
1988
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
2003
Monoclonal Antibody Therapy for Cancer
2003
Characterization of insulin-like growth factor 1 in human primary brain tumors.
1993
Disrupting insulin-like growth factor signaling as a potential cancer therapy
2007
Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1
1999
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
The mammary gland
1991
HER2 as a Predictor of Therapeutic Response in Breast Cancer
2000
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
Expression of hypoxia-inducible factor 1? in brain tumors
2000 StandoutNobel
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells.
1996
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
2005
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
2005
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
1998
Works of Ester B. Coronado being referenced
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
1992
Insulin-Like Growth Factor-ll (IGF-II): A Potential Autocrine/Paracrine Growth Factor for Human Breast Cancer Acting via the IGF-I Receptor
1989
Blockade of the Epidermal Growth Factor Receptor Inhibits Transforming Growth Factor α-Induced but Not Estrogen-Induced Growth of Hormone-Dependent Human Breast Cancer
1988
Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapy
1987
Insulin-Like Growth Factor Binding Protein Secretion by Breast Carcinoma Cell Lines: Correlation with Estrogen Receptor Status*
1990
Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen
1991
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
1994
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model
1988
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.
1989
Tumor and serum tamoxifen concentrations in the athymic nude mouse
1989
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
1994